AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ACRX
CUSIPN/A
Phone650-216-3500
Debt
Debt-to-Equity Ratio-0.15
Current Ratio4.01
Quick Ratio3.96
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$7.99 million
Price / Sales29.96
Cash FlowN/A
Price / CashN/A
Book Value($0.73) per share
Price / Book-5.41
Profitability
EPS (Most Recent Fiscal Year)($1.10)
Net Income$-51,500,000.00
Net Margins-1,329.13%
Return on EquityN/A
Return on Assets-62.39%
Miscellaneous
Employees41
Outstanding Shares60,600,000
Market Cap$239.37 million
AcelRx Pharmaceuticals (NASDAQ:ACRX) Frequently Asked Questions
What is AcelRx Pharmaceuticals' stock symbol?
AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX."
How were AcelRx Pharmaceuticals' earnings last quarter?
AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) posted its quarterly earnings data on Thursday, August, 2nd. The specialty pharmaceutical company reported ($0.20) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.19) by $0.01. The specialty pharmaceutical company had revenue of $0.82 million for the quarter, compared to analyst estimates of $0.93 million. View AcelRx Pharmaceuticals' Earnings History.
When is AcelRx Pharmaceuticals' next earnings date?
What price target have analysts set for ACRX?
8 equities research analysts have issued twelve-month price targets for AcelRx Pharmaceuticals' shares. Their predictions range from $2.00 to $8.00. On average, they expect AcelRx Pharmaceuticals' share price to reach $5.50 in the next twelve months. This suggests a possible upside of 39.2% from the stock's current price. View Analyst Price Targets for AcelRx Pharmaceuticals.
What is the consensus analysts' recommendation for AcelRx Pharmaceuticals?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AcelRx Pharmaceuticals in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AcelRx Pharmaceuticals.
What are Wall Street analysts saying about AcelRx Pharmaceuticals stock?
Here are some recent quotes from research analysts about AcelRx Pharmaceuticals stock:
- 1. Cantor Fitzgerald analysts commented, "Zalviso offer advantages to the patient, physician/nurse and the treatment facility, that if approved and priced accordingly, we believe will drive uptake of both products beyond the Street’s current estimates which should drive the stock higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $6." (9/20/2018)
- 2. According to Zacks Investment Research, "AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and ARX-03 or the Sufentanil/Triazolam NanoTab which are in their development stage. Its product ARX-01 is focused on acute post-operative pain, ARX-02 is focused on the treatment of cancer breakthrough pain and ARX-03 is focused on providing mild sedation, anxiety reduction, and pain relief to patients undergoing painful procedures in a physician's office. AcelRx Pharmaceuticals, Inc. is headquartered in Redwood City, California. " (8/14/2018)
Are investors shorting AcelRx Pharmaceuticals?
AcelRx Pharmaceuticals saw a drop in short interest in August. As of August 15th, there was short interest totalling 3,205,974 shares, a drop of 28.5% from the July 31st total of 4,483,807 shares. Based on an average daily volume of 565,334 shares, the short-interest ratio is currently 5.7 days. Currently, 6.1% of the shares of the stock are short sold. View AcelRx Pharmaceuticals' Current Options Chain.
Who are some of AcelRx Pharmaceuticals' key competitors?
Some companies that are related to AcelRx Pharmaceuticals include MacroGenics (MGNX), Revance Therapeutics (RVNC), Rocket Pharmaceuticals (RCKT), Assembly Biosciences (ASMB), Cara Therapeutics (CARA), Aptinyx (APTX), Amphastar Pharmaceuticals (AMPH), Amarin (AMRN), Radius Health (RDUS), CytomX Therapeutics (CTMX), Homology Medicines (FIXX), ProQR Therapeutics (PRQR), Inflarx (IFRX), Dynavax Technologies (DVAX) and Crinetics Pharmaceuticals (CRNX).
Who are AcelRx Pharmaceuticals' key executives?
AcelRx Pharmaceuticals' management team includes the folowing people:
- Mr. Vincent J. Angotti, CEO & Director (Age 50)
- Dr. Pamela Pierce Palmer, Co-Founder, Chief Medical Officer & Director (Age 55)
- Mr. Raffi Mark Asadorian, Chief Financial Officer (Age 49)
- Mr. Lawrence G. Hamel, Chief Devel. Officer (Age 66)
- Mr. Anil N. Dasu, Chief Engineering Officer (Age 55)
Who are AcelRx Pharmaceuticals' major shareholders?
AcelRx Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (1.11%), Renaissance Technologies LLC (0.82%), FMR LLC (0.49%), Northern Trust Corp (0.12%), Granite Investment Partners LLC (0.10%) and Lincoln Capital Corp (0.07%). Company insiders that own AcelRx Pharmaceuticals stock include Lawrence G Hamel, Life Sciences Maste Perceptive, Mark G Edwards, Pamela P Palmer, Perceptive Advisors Llc, Raffi Asadorian and Vincent J Angotti. View Institutional Ownership Trends for AcelRx Pharmaceuticals.
Which institutional investors are selling AcelRx Pharmaceuticals stock?
Which institutional investors are buying AcelRx Pharmaceuticals stock?
ACRX stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, FMR LLC, Granite Investment Partners LLC, Lincoln Capital Corp and BlackRock Inc.. Company insiders that have bought AcelRx Pharmaceuticals stock in the last two years include Mark G Edwards, Pamela P Palmer, Raffi Asadorian and Vincent J Angotti. View Insider Buying and Selling for AcelRx Pharmaceuticals.
How do I buy shares of AcelRx Pharmaceuticals?
Shares of ACRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AcelRx Pharmaceuticals' stock price today?
One share of ACRX stock can currently be purchased for approximately $3.95.
How big of a company is AcelRx Pharmaceuticals?
AcelRx Pharmaceuticals has a market capitalization of $239.37 million and generates $7.99 million in revenue each year. The specialty pharmaceutical company earns $-51,500,000.00 in net income (profit) each year or ($1.10) on an earnings per share basis. AcelRx Pharmaceuticals employs 41 workers across the globe.
What is AcelRx Pharmaceuticals' official website?
How can I contact AcelRx Pharmaceuticals?
AcelRx Pharmaceuticals' mailing address is 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063. The specialty pharmaceutical company can be reached via phone at 650-216-3500 or via email at [email protected]
MarketBeat Community Rating for AcelRx Pharmaceuticals (NASDAQ ACRX)
MarketBeat's community ratings are surveys of what our community members think about AcelRx Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
